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ABSTRACT
Microbiological analysis of a urine sample from
an outpatient with symptoms of urinary infection
detected >105 CFU ⁄mL urine of Salmonella enterica
serotype Virchow with resistance to cefotaxime.
Molecular analysis demonstrated the presence of
the gene encoding CTX-M-10 b-lactamase in this
clinical isolate. This is the first report of this
enzyme in Salmonella spp.
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A urine sample from a female aged 27 years with
symptoms of urinary tract infection was sent to
Complejo Hospitalario Universitario Juan Canal-
ejo (La Corun˜a, Spain) from a primary care
centre in La Corun˜a during June 2002. The urine
sample contained >105 CFU ⁄mL of urine of
Salmonella enterica subspecies I, serotype Virchow
(6,7:r:1,2); the isolate was designated SeJC40682.
Susceptibility testing demonstrated resistance or
reduced susceptibility to most b-lactam antibio-
tics tested, including amoxycillin, ticarcillin,
piperacillin, cefazolin, cefuroxime and cefotaxi-
me (Table 1), as well as pipemidic acid, nalidixic
acid and nitrofurantoin, but the isolate remained
susceptible to fluoroquinolones, aminoglyco-
sides, co-trimoxazole and fosfomycin.
Although susceptible to ceftazidime, synergy
was observed between clavulanic acid and cefo-
taxime, compatible with the production of an
extended-spectrum b-lactamase (ESBL). b-Lacta-
mases were extracted by sonication from the
clinical isolate, subjected to isoelectric focusing
(IEF) in a PhastSystem (PhastGel IEF 3–9; Phar-
macia AB, Uppsala, Sweden), and detected with
nitrocefin 0.5 mg ⁄mL (Oxoid, Basingstoke, UK).
Semi-purified sonicated extracts of b-lactamases
with known isoelectric points (pIs) were used as
standards. The clinical isolate yielded a single
b-lactamase band of pI 8.0, very similar to that
yielded by Escherichia coli isolates obtained from
this area during a previous study in 2001, which
were shown subsequently to produce CTX-M-14
[1]. This information, combined with the fact that
the MIC of cefotaxime for SeJC40682 was signifi-
cantly higher than that of ceftazidime, suggested
the presence of a CTX-M enzyme in this clinical
isolate.
As most CTX-M enzymes to date have been
plasmid-mediated, conjugation experiments [1]
were performed with the E. coli XL1-Blue
MRF’Kan strain (Stratagene Europe, Amsterdam,
The Netherlands) as the recipient strain, and a
previously characterised clinical isolate of E. coli
harbouring a plasmid-mediated CTX-M-14 gene
as a positive control. However, no transconju-
gants were obtained with SeJC40682 as the donor,
and no plasmid was detected in SeJC40682 fol-
lowing attempts to isolate plasmid DNA [1]
(results not shown).
Chromosomal DNA from clinical strain
SeJC40682 was purified with a MasterPure DNA
Purification Kit (Epicentre, Madison, WI, USA).
The DNA preparation (500 ng) was then subjec-
ted to PCR using the following sets of primers
(Sigma-Genosys, Cambridge, UK), which amplify
the five groups of CTX-M enzymes that have
been described to date [2]: (i) CTX-M-1 group,
5¢-ATGGCGACGGCAACCGTCA and 5¢-CAAA-
CCGTTGGTGACGATTTTA; (ii) CTX-M-2 group,
5¢-ATGATGACTCAGAGCATTCG and 5¢-TCA-
GAAACCGTGGGTTACG; (iii) CTX-M-8 group,
5¢-ATGATGAGACATCGCGTTAAG and 5¢-TT-
AATAACCGTCGGTGACGAT; (iv) CTX-M-25
group, 5¢-ATGATGAGAAAAAGCGTAAG and
5¢-TTAATAACCGTCGGTGACAA; and (v) CTX-
M-9 group, for which two forward primers were
used because of the presence of polymorphisms
in the 5¢ region of these genes in this group,
5¢-ATGGTGACAAAGAGAATG and 5¢-ATGGT-
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GACAAAGAGAGTGC, with 5¢-TTACAGCCCT-
TCGGCATG as reverse primer.
After amplification, DNA fragments were sep-
arated on agarose 0.8% w ⁄ v gels and visualised
following staining with ethidium bromide
50 mg ⁄L. Amplification occurred only with the
CTX-M-1 group primers, yielding an amplicon
of c. 0.9 kb. Sequencing of this amplicon [1],
together with the deduced amino-acid sequence,
showed that the corresponding gene encoded a
CTX-M-10 b-lactamase.
The CTX-M-10 b-lactamase was characterised
following its isolation from a clinical isolate of
E. coli [3]. CTX-M-10 belongs to the CTX-M-1
group, and is derived from the CTX-M-1 enzyme
with the following amino-acid replacements:
Ala27Val; Arg38Gln; Val77Ala; Asp114Asn;
Ser140Ala; and Asn288Asp. Amino-acid numbers
were assigned as described by Ambler et al. [4].
The microbiological and biochemical findings
showed the typical cefotaximase CTX-M profile,
with resistance to cefotaxime and susceptibility to
ceftazidime in an E. coli strain expressing this
enzyme. Specific sequences of the CTX-M-10
gene, comprising the promoter and 3¢ untranslat-
ed regions, together with BamHI and EcoRI
restriction site adaptors (5¢- AAGGATCCCTGG-
CAGTGCAAAATTTATCG and 5¢- AAGAATT-
CATCAGGAGCCACAGAGCTTATG) were used
in a new PCR with SeJC40682 chromosomal DNA
as the template. A 1.1-kb amplicon was cloned [1]
into the pBGS18 plasmid (conferring resistance to
kanamycin) at the BamHI and EcoRI restriction
sites, and transformants were selected in the
E. coli TG1 host. The recombinant plasmid was
named pMC-C. When MICs of b-lactam antibiot-
ics were determined with transformants harbour-
ing pMC-C (Table 1), the susceptibility profile
was almost identical to that described previously
for CTX-M-10 [3].
Following confirmation of the presence of the
CTX-M-10 gene, a Southern blot experiment was
performed with SeJC40682 to eliminate the pos-
sibility of a plasmid-based location for the CTX-
M-10 gene. The results demonstrated that the
CTX-M-10 gene was chromosomally encoded in
SeJC40682 (data not shown).
CTX-M b-lactamases are becoming increasingly
important worldwide [2]. To date, >40 different
enzymes have been reported and classified into five
groups on the basis of their amino-acid sequence
homologies [2]. CTX-M-10 b-lactamase has been
described previously in Enterobacteriaceae in Spain
[2,3,5,6]. Isolates of Salmonella spp. have been found
in Europe and SouthAmerica that harbour CTX-M-
2,-3,-4,-9 and -14 enzymes in serotypes Typhimu-
rium and Enteriditis [2,7,8]. In Spain, Simarro et al.
[7] detected CTX-M-9 in four isolates of S. enterica
Virchow fromBarcelona andMurcia,while Romero
et al. [8] detected the CTX-M-14 gene in S. enterica
serotype Enteriditis on a conjugative plasmid. The
present study reports the first observation of CTX-
M-10 in S. enterica serotype Virchow. It is notewor-
thy that the patient with the urinary tract infection
caused by this isolate hadnot had any contactwith a
hospital before the isolation of this resistant organ-
ism, thereby providing further evidence that these
b-lactamases may be becoming established in the
community setting [1].
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ABSTRACT
The characteristics of spontaneous aerobic Gram-
negative bacillary meningitis (AGNBM) were
determined in 40 adults requiring admission to
an intensive care unit (ICU) during a 16-year
period in ten French ICUs. Eight infections were
hospital-acquired and most patients had predis-
posing factors, mainly chronic alcoholism and an
immunocompromised status. Three immunosup-
pressed patients had disseminated strongyloidia-
sis. Gram’s stain, cerebrospinal fluid and blood
cultures were positive for 85%, 98% and 80% of
cases, respectively. Escherichia coli (57%) and
Klebsiella pneumoniae (17%) were the most fre-
quent pathogens. In-ICU mortality was 38%.
Spontaneous AGNBM is a rare complication of
bacteraemia in adults. The severity of predispo-
sing underlying diseases might explain the poor
prognosis despite appropriate antimicrobial
therapy.
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Spontaneous aerobic Gram-negative bacillary
meningitis (AGNBM) in adults is uncommon in
Western countries, having been reported in only
4% and 0.7% of patients with community-
acquired bacterial meningitis in the USA and
Europe, respectively [1–4]. In contrast, AGNBM,
especially that caused by Klebsiella pneumoniae, is
more frequent in some other areas, e.g., Taiwan
[5]. Most studies dealing with AGNBM include
patients with post-trauma or neurosurgical men-
ingitis and spontaneous episodes, without delin-
eating clearly among the specific characteristics of
the latter [6–9]. The present study determined the
clinical characteristics and outcome of sponta-
neous AGNBM in adults requiring admission to
intensive care units (ICUs) in France. The charts
of consecutive patients aged > 16 years with
AGNBM who were admitted to ten ICUs in
France between January 1988 and July 2003 were
analysed retrospectively. Patients were included
if they had cerebrospinal fluid pleocytosis
(> 10 cells ⁄ lL) with a predominance of polymor-
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